SCHEMBL4483279

SCHEMBL4483279

Cc1[nH]c(C)c(-c2ccc(-c3cc(C(F)(F)F)cc(C(F)(F)F)c3)nc2)c(=O)c1Br

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.58
KDM1A O60341 3/20 0.39
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
IKBKB O14920 1/20 0.35
DGAT1 O75907 5/20 0.34
SLC11A2 P49281 1/20 0.34
ALOX5AP P20292 1/20 0.34
FEN1 P39748 1/20 0.34
PDE2A O00408 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
KIF11 P52732 1/20 0.32
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4472787 0.91 SLC2A1 (0.58) SLC2A1KDM1ADGAT1SLC11A2PDE2A
SCHEMBL4493390 0.90 SLC2A1 (0.66) SLC2A1KDM1AIKBKBSLC11A2TDP1
SCHEMBL4476390 0.84 SLC2A1 (0.56) SLC2A1DGAT1ALOX5APFEN1
SCHEMBL4464652 0.82 SLC2A1 (0.47) SLC2A1SLC11A2
SCHEMBL4493325 0.81 SLC2A1 (0.84) SLC2A1PSEN1PSEN2APH1BNCSTN
SCHEMBL4480432 0.81 SLC2A1 (0.50) SLC2A1DGAT1
SCHEMBL4490477 0.80 SLC2A1 (0.48) SLC2A1DGAT1
SCHEMBL4489336 0.80 SLC2A1 (0.52) SLC2A1ALOX5APFEN1
SCHEMBL4487868 0.79 SLC2A1 (0.45) SLC2A1KDM1AIKBKB
SCHEMBL9263676 0.78 SLC2A1 (0.53) SLC2A1SLC11A2KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US claimed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US claimed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
EP-1858876-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006094799-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP SLC2A1 2278/4885KDM1A 1359/4885PSEN1 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.